Abstract
Introduction: Older adults with chronic schizophrenia are at greater risk for functional disability and poorer health outcomes than those without serious mental illness. This population makes up 1% to 2% of the elderly population in the United States and is projected to number approximately 15 million by 2030. The symptoms of schizophrenia can be disabling for individuals, significantly reducing their quality of life. Often, the negative symptoms are the most resistant to treatment and are considered a marker of illness severity, though challenging to objectively measure. Biomarkers can provide an objective indicator of health status. Brain Derived Neurotrophic Factor (BDNF) is a potential biomarker for schizophrenia and may serve as an important indicator of illness severity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
